{"hands_on_practices": [{"introduction": "The defining feature of lysosomal storage diseases is the pathological accumulation of undigested macromolecules. This exercise provides a quantitative model to explore this phenomenon, applying the principles of enzyme kinetics to a simplified lysosomal system. By calculating the steady-state substrate concentration, you will discover how even a minor deficiency in a lysosomal enzyme, operating near its saturation point, can lead to a dramatic and disproportionate increase in stored substrate, offering a clear mathematical basis for the disease's pathophysiology. [@problem_id:4801208]", "problem": "A macrophage from a patient with an inherited lysosomal storage disease (deficiency of the hydrolase that degrades a sphingolipid) accumulates its lysosomal substrate because degradation is saturable while biosynthetic delivery is approximately constant. Assume a single, well-mixed lysosomal compartment with a constant substrate delivery (production) rate $P$ and a single removal pathway catalyzed by the residual lysosomal enzyme following saturable kinetics characterized by a maximal catalytic capacity $V_{\\max}$ and a Michaelis constant $K_{m}$. At steady state, the lysosomal substrate concentration $[S]$ does not change in time.\n\nGiven $P = 0.97\\,\\mu\\text{M}\\,\\text{min}^{-1}$, $V_{\\max} = 1.00\\,\\mu\\text{M}\\,\\text{min}^{-1}$, and $K_{m} = 11.3\\,\\mu\\text{M}$, compute the steady-state lysosomal substrate concentration $[S]$. Round your answer to three significant figures and express it in micromolar ($\\mu\\text{M}$).\n\nThen, starting from fundamental mass balance and the definition of saturable enzyme kinetics, provide a symbolic derivation in your reasoning that explains why, in the regime $[S]\\gg K_{m}$, small fractional increases in $V_{\\max}$ produce large fractional decreases in $[S]$. Do not report any additional numerical value beyond the requested $[S]$; your analysis should be conceptual and symbolic.", "solution": "The problem asks for the computation of the steady-state substrate concentration in a lysosomal compartment and for a symbolic derivation of the sensitivity of this concentration to changes in the maximal enzymatic rate.\n\nThe dynamic of the lysosomal substrate concentration, denoted as $[S]$, is governed by a mass balance equation. The rate of change of $[S]$ with respect to time $t$, $\\frac{d[S]}{dt}$, is the difference between the substrate production (delivery) rate, $P$, and its removal (degradation) rate, $V$.\n\n$$\n\\frac{d[S]}{dt} = \\text{Production Rate} - \\text{Removal Rate}\n$$\n\nThe production rate is given as a constant, $P$. The removal is catalyzed by an enzyme following saturable, Michaelis-Menten kinetics. The rate of this enzymatic reaction, $V$, is given by:\n\n$$\nV = \\frac{V_{\\max} [S]}{K_{m} + [S]}\n$$\n\nHere, $V_{\\max}$ is the maximal catalytic capacity of the enzyme, and $K_{m}$ is the Michaelis constant, which is the substrate concentration at which the reaction rate is half of $V_{\\max}$.\n\nThe mass balance equation is therefore:\n\n$$\n\\frac{d[S]}{dt} = P - \\frac{V_{\\max} [S]}{K_{m} + [S]}\n$$\n\nAt steady state, the concentration of the substrate does not change over time, meaning $\\frac{d[S]}{dt} = 0$. This implies that the production rate is exactly balanced by the removal rate.\n\n$$\nP = \\frac{V_{\\max} [S]}{K_{m} + [S]}\n$$\n\nWe are tasked with solving this equation for the steady-state substrate concentration, $[S]$. We can rearrange the equation algebraically:\n\n$$\nP(K_{m} + [S]) = V_{\\max} [S]\n$$\n$$\nP K_{m} + P [S] = V_{\\max} [S]\n$$\n$$\nP K_{m} = V_{\\max} [S] - P [S]\n$$\n$$\nP K_{m} = [S] (V_{\\max} - P)\n$$\n\nIsolating $[S]$ gives the symbolic expression for the steady-state substrate concentration:\n\n$$\n[S] = \\frac{P K_{m}}{V_{\\max} - P}\n$$\n\nThis expression is valid for $P < V_{\\max}$. If $P \\ge V_{\\max}$, no stable steady state is possible, and the substrate would accumulate indefinitely.\n\nNow, we substitute the given numerical values into this expression:\n$P = 0.97\\,\\mu\\text{M}\\,\\text{min}^{-1}$\n$V_{\\max} = 1.00\\,\\mu\\text{M}\\,\\text{min}^{-1}$\n$K_{m} = 11.3\\,\\mu\\text{M}$\n\n$$\n[S] = \\frac{(0.97\\,\\mu\\text{M}\\,\\text{min}^{-1})(11.3\\,\\mu\\text{M})}{1.00\\,\\mu\\text{M}\\,\\text{min}^{-1} - 0.97\\,\\mu\\text{M}\\,\\text{min}^{-1}}\n$$\n$$\n[S] = \\frac{10.961\\,(\\mu\\text{M})^2\\,\\text{min}^{-1}}{0.03\\,\\mu\\text{M}\\,\\text{min}^{-1}}\n$$\n$$\n[S] = 365.366... \\,\\mu\\text{M}\n$$\n\nThe problem requires rounding the answer to three significant figures.\n\n$$\n[S] \\approx 365\\,\\mu\\text{M}\n$$\n\nFor the second part of the problem, we must derive why, in the regime $[S] \\gg K_{m}$, small fractional increases in $V_{\\max}$ produce large fractional decreases in $[S]$.\n\nThe fractional change in a variable $x$ is given by $\\frac{dx}{x}$, which is equivalent to $d(\\ln x)$. We are interested in the relationship between the fractional change in $[S]$ and the fractional change in $V_{\\max}$. This relationship is quantified by the logarithmic sensitivity (or elasticity) of $[S]$ with respect to $V_{\\max}$, defined as $S_{V_{\\max}}^{[S]} = \\frac{\\partial \\ln[S]}{\\partial \\ln V_{\\max}}$.\n\n$$\nS_{V_{\\max}}^{[S]} = \\frac{\\partial (\\ln[S])}{\\partial (\\ln V_{\\max})} = \\frac{V_{\\max}}{[S]} \\frac{\\partial [S]}{\\partial V_{\\max}}\n$$\n\nTo find $\\frac{\\partial [S]}{\\partial V_{\\max}}$, we can differentiate the symbolic expression for $[S]$ with respect to $V_{\\max}$, treating $P$ and $K_{m}$ as constants:\n\n$$\n[S] = P K_{m} (V_{\\max} - P)^{-1}\n$$\n$$\n\\frac{\\partial [S]}{\\partial V_{\\max}} = P K_{m} \\cdot (-1) (V_{\\max} - P)^{-2} \\cdot (1) = -\\frac{P K_{m}}{(V_{\\max} - P)^2}\n$$\n\nNow, we substitute this derivative back into the sensitivity expression:\n\n$$\nS_{V_{\\max}}^{[S]} = \\frac{V_{\\max}}{[S]} \\left( -\\frac{P K_{m}}{(V_{\\max} - P)^2} \\right)\n$$\n\nWe also substitute the expression for $[S]$ itself, $[S] = \\frac{P K_{m}}{V_{\\max} - P}$:\n\n$$\nS_{V_{\\max}}^{[S]} = \\frac{V_{\\max}}{\\frac{P K_{m}}{V_{\\max} - P}} \\left( -\\frac{P K_{m}}{(V_{\\max} - P)^2} \\right)\n$$\n$$\nS_{V_{\\max}}^{[S]} = \\frac{V_{\\max} (V_{\\max} - P)}{P K_{m}} \\left( -\\frac{P K_{m}}{(V_{\\max} - P)^2} \\right)\n$$\n\nCanceling terms ($P K_m$ and one factor of $V_{\\max} - P$) simplifies the expression significantly:\n\n$$\nS_{V_{\\max}}^{[S]} = - \\frac{V_{\\max}}{V_{\\max} - P}\n$$\n\nThe problem specifies the regime where $[S] \\gg K_{m}$. This condition means the enzyme is highly saturated with its substrate. In this state, the enzymatic removal rate $V = \\frac{V_{\\max}[S]}{K_m + [S]}$ approaches its maximum value, $V_{\\max}$, because the denominator $K_m + [S] \\approx [S]$.\n\nAt steady state, $P = V$. Therefore, for the system to be in a steady state where $[S] \\gg K_{m}$, the production rate $P$ must be very close to, but slightly less than, the maximal removal rate $V_{\\max}$. This can be expressed as $P \\approx V_{\\max}$ or $V_{\\max} - P = \\delta$, where $\\delta$ is a small positive quantity.\n\nSubstituting this into our sensitivity expression:\n\n$$\nS_{V_{\\max}}^{[S]} = - \\frac{V_{\\max}}{\\delta}\n$$\n\nSince $V_{\\max}$ is a finite positive constant and $\\delta$ is a very small positive number, the ratio $-\\frac{V_{\\max}}{\\delta}$ is a large negative number. The interpretation of this large negative sensitivity, $S_{V_{\\max}}^{[S]} = \\frac{\\Delta [S]/[S]}{\\Delta V_{\\max}/V_{\\max}}$, is that a small fractional increase in $V_{\\max}$ (a small positive $\\Delta V_{\\max}/V_{\\max}$) leads to a large fractional decrease in $[S]$ (a large negative $\\Delta [S]/[S]$).\n\nThis explains the high sensitivity of the accumulated substrate to residual enzyme activity in lysosomal storage diseases. Even a minor improvement in the enzyme's maximal capacity can lead to a dramatic reduction in the pathological substrate accumulation, especially when the system is operating near the brink of saturation ($P \\approx V_{\\max}$).", "answer": "$$\n\\boxed{365}\n$$", "id": "4801208"}, {"introduction": "While lysosomal disorders are about 'storage,' mitochondrial diseases are fundamentally about 'energy failure.' This practice moves from metabolic waste to energy currency, guiding you through a bioenergetic calculation based on the chemiosmotic theory. You will quantify the precise impact of a defect in the mitochondrial electron transport chain on the cell's total ATP yield per glucose molecule, thereby translating a molecular lesion into a concrete physiological deficit. [@problem_id:4801196]", "problem": "A researcher is modeling oxidative phosphorylation (OXPHOS) efficiency in a patient with an inherited Complex I deficiency consistent with a primary mitochondrial disorder affecting nicotinamide adenine dinucleotide dehydrogenase (Complex I). The goal is to quantify the energetic impact of reduced coupling and reduced Complex I activity on adenosine triphosphate (ATP) production per glucose. Use the chemiosmotic framework and the following well-tested facts as the fundamental base:\n\n- Electrons from mitochondrial reduced nicotinamide adenine dinucleotide (NADH) drive proton pumping of $10$ protons across the inner mitochondrial membrane via Complex I, Complex III, and Complex IV in total.\n- Electrons from reduced flavin adenine dinucleotide (FADH$_2$) (entering at Complex II) result in $6$ protons pumped (Complex III and Complex IV only).\n- The synthesis of one cytosolic ATP and its export require a net of $4$ protons, accounting for the rotary adenosine triphosphate synthase (ATP synthase), the phosphate carrier, and the adenine nucleotide translocase.\n- Define the coupling efficiency $\\eta$ as the fraction of pumped protons that are actually used to make ATP (the remainder is lost to proton leak and slippage).\n- Assume that complete oxidation of $1$ molecule of glucose yields $10$ mitochondrial NADH and $2$ FADH$_2$ (malateâ€“aspartate shuttle is operative), plus $4$ substrate-level ATP equivalents that are independent of OXPHOS.\n- In control mitochondria, the coupling efficiency is $\\eta_{\\text{control}} = 0.85$. In the patient, increased proton leak reduces coupling to $\\eta_{\\text{patient}} = 0.65$. The fractional Complex I activity in the patient is $\\alpha = 0.70$ relative to control, whereas Complex II, III, and IV are unaffected.\n\nTasks:\n\n- Using the above base, derive expressions for ATP yield per NADH and per FADH$_2$ as functions of coupling efficiency $\\eta$.\n- Evaluate these yields for $\\eta_{\\text{control}}$ and for $\\eta_{\\text{patient}}$.\n- Compute total ATP per glucose in control and in the patient, treating the Complex I deficiency as a proportional reduction of the NADH-derived OXPHOS yield by the factor $\\alpha$, while leaving FADH$_2$-derived OXPHOS yield and substrate-level phosphorylation unchanged.\n- Determine the ATP shortfall per glucose in the patient relative to control.\n\nRound your final answer to four significant figures. Express the final shortfall in ATP molecules per glucose. Provide only the final shortfall as your answer.", "solution": "The problem is validated as scientifically grounded, well-posed, and objective. The provided data and definitions are consistent with standard models of mitochondrial bioenergetics.\n\nThe solution proceeds by first deriving general expressions for adenosine triphosphate (ATP) yield, then calculating the total ATP production per glucose for a control subject and a patient, and finally determining the difference.\n\n**Step 1: Derivation of ATP Yields**\nThe ATP yield per substrate, often referred to as the P/O ratio, is determined by the number of protons pumped across the inner mitochondrial membrane per substrate molecule oxidized, the coupling efficiency $\\eta$, and the number of protons required to synthesize and transport one molecule of ATP into the cytosol.\n\nLet $H^{+}_{\\text{NADH}}$ be the number of protons pumped per mitochondrial reduced nicotinamide adenine dinucleotide (NADH), and $H^{+}_{\\text{FADH}_2}$ be the number of protons pumped per reduced flavin adenine dinucleotide (FADH$_2$).\nWe are given:\n$H^{+}_{\\text{NADH}} = 10$\n$H^{+}_{\\text{FADH}_2} = 6$\nLet $H^{+}_{\\text{ATP}}$ be the number of protons consumed for the synthesis and export of one ATP molecule.\nWe are given:\n$H^{+}_{\\text{ATP}} = 4$\n\nThe coupling efficiency, $\\eta$, is the fraction of pumped protons that are effectively used for ATP synthesis, with the fraction ($1 - \\eta$) being lost to processes like proton leak.\nThe ATP yield per NADH, $Y_{\\text{NADH}}$, as a function of $\\eta$ is:\n$$Y_{\\text{NADH}}(\\eta) = \\frac{\\eta \\times H^{+}_{\\text{NADH}}}{H^{+}_{\\text{ATP}}} = \\frac{10\\eta}{4} = 2.5\\eta$$\nThe ATP yield per FADH$_2$, $Y_{\\text{FADH}_2}$, as a function of $\\eta$ is:\n$$Y_{\\text{FADH}_2}(\\eta) = \\frac{\\eta \\times H^{+}_{\\text{FADH}_2}}{H^{+}_{\\text{ATP}}} = \\frac{6\\eta}{4} = 1.5\\eta$$\n\n**Step 2: Total ATP Yield per Glucose for the Control**\nThe complete oxidation of one molecule of glucose yields $10$ mitochondrial NADH, $2$ FADH$_2$, and $4$ ATP from substrate-level phosphorylation ($ATP_{\\text{SLP}}$). The total ATP, $ATP_{\\text{total}}$, is the sum of contributions from substrate-level phosphorylation and oxidative phosphorylation.\n$$ATP_{\\text{total}} = ATP_{\\text{SLP}} + 10 \\cdot Y_{\\text{NADH}} + 2 \\cdot Y_{\\text{FADH}_2}$$\nFor the control, the coupling efficiency is $\\eta_{\\text{control}} = 0.85$.\nThe specific yields are:\n$Y_{\\text{NADH, control}} = 2.5 \\eta_{\\text{control}} = 2.5 \\times 0.85 = 2.125$\n$Y_{\\text{FADH}_2, control} = 1.5 \\eta_{\\text{control}} = 1.5 \\times 0.85 = 1.275$\nThe total ATP per glucose for the control subject is:\n$$ATP_{\\text{total, control}} = 4 + 10 \\times (2.125) + 2 \\times (1.275)$$\n$$ATP_{\\text{total, control}} = 4 + 21.25 + 2.55 = 27.8$$\n\n**Step 3: Total ATP Yield per Glucose for the Patient**\nFor the patient, two parameters are changed: the coupling efficiency is reduced to $\\eta_{\\text{patient}} = 0.65$, and the fractional Complex I activity is $\\alpha = 0.70$.\n\nThe ATP production from FADH$_2$ is affected only by the reduced coupling efficiency, as FADH$_2$ feeds electrons into Complex II, bypassing Complex I.\n$Y_{\\text{FADH}_2, patient} = 1.5 \\eta_{\\text{patient}} = 1.5 \\times 0.65 = 0.975$\nThe contribution from FADH$_2$ is:\n$$ATP_{\\text{FADH}_2, patient} = 2 \\cdot Y_{\\text{FADH}_2, patient} = 2 \\times 0.975 = 1.95$$\n\nThe ATP production from NADH is affected by both the reduced coupling efficiency and the reduced Complex I activity. First, we calculate the hypothetical yield based on the patient's coupling efficiency alone:\n$Y_{\\text{NADH, patient (uncorrected)}} = 2.5 \\eta_{\\text{patient}} = 2.5 \\times 0.65 = 1.625$\nThe problem states that the Complex I deficiency leads to a proportional reduction of the *NADH-derived OXPHOS yield* by the factor $\\alpha$. Therefore, the total ATP from the $10$ NADH molecules is scaled by $\\alpha$.\n$$ATP_{\\text{NADH, patient}} = \\alpha \\times (10 \\cdot Y_{\\text{NADH, patient (uncorrected)}})$$\n$$ATP_{\\text{NADH, patient}} = 0.70 \\times (10 \\times 1.625) = 0.70 \\times 16.25 = 11.375$$\n\nThe total ATP per glucose for the patient is the sum of the unchanged substrate-level phosphorylation and the affected oxidative phosphorylation contributions:\n$$ATP_{\\text{total, patient}} = ATP_{\\text{SLP}} + ATP_{\\text{NADH, patient}} + ATP_{\\text{FADH}_2, patient}$$\n$$ATP_{\\text{total, patient}} = 4 + 11.375 + 1.95 = 17.325$$\n\n**Step 4: ATP Shortfall per Glucose**\nThe ATP shortfall in the patient relative to the control is the difference in their total ATP yields per glucose.\n$$ \\text{Shortfall} = ATP_{\\text{total, control}} - ATP_{\\text{total, patient}} $$\n$$ \\text{Shortfall} = 27.8 - 17.325 = 10.475 $$\nThe problem requires the answer to be rounded to four significant figures.\n$$ \\text{Shortfall} \\approx 10.48 $$", "answer": "$$\\boxed{10.48}$$", "id": "4801196"}, {"introduction": "Mitochondrial DNA follows a unique pattern of maternal inheritance that is complicated by the random segregation of mitochondria during egg cell formation, a phenomenon known as the 'genetic bottleneck.' This advanced practice employs a probabilistic model to simulate this process and calculate the risk of an offspring inheriting a clinically significant level of mutant mtDNA. This exercise illuminates why the severity of mitochondrial diseases can vary so widely and unpredictably among family members, moving beyond simple Mendelian genetics to the realm of stochastic biological processes. [@problem_id:4801213]", "problem": "In inherited mitochondrial diseases, a heteroplasmic mutation in mitochondrial deoxyribonucleic acid (mtDNA) leads to clinical manifestations when the proportion of mutant genomes exceeds a pathogenic threshold. Consider a mother with mutant mtDNA heteroplasmy proportion $h$ (the fraction of mutant molecules among all mtDNA molecules). During oogenesis, the mitochondrial genetic bottleneck can be modeled as $n$ independent draws of individual mtDNA genomes from the maternal pool, each draw resulting in a mutant genome with probability $h$ and a wild-type genome with probability $1 - h$. Let the offspring carry $k$ mutant mtDNA molecules among the $n$ molecules that determine the early embryonic heteroplasmy, so the offspring heteroplasmy is $k/n$. Disease is predicted to manifest if the offspring heteroplasmy meets or exceeds a pathogenic threshold $h_c$ (with $0 < h_c < 1$). Assume no selection, no replication skew, and independence of sampling.\n\nUsing only the fundamental definitions of Bernoulli trials and the binomial distribution arising from independent sampling, derive a closed-form analytic expression for the probability that the offspring heteroplasmy meets or exceeds the pathogenic threshold, that is, for $\\mathbb{P}\\!\\left(k/n \\ge h_c\\right)$, as a function of $h$, $h_c$, and $n$. You may express your final result in terms of standard special functions. Provide your final answer as a single closed-form analytical expression. No numerical evaluation is required. If you introduce any special functions, define them clearly in your derivation. The final answer must be a single expression; do not present an inequality or an equation as the final answer.", "solution": "The problem statement is evaluated to be scientifically grounded, well-posed, objective, and complete. It describes a standard binomial sampling model, which is a valid and widely used simplification for studying the genetic bottleneck in mitochondrial inheritance. All parameters are clearly defined, and the objective is a formal derivation of a probability. Therefore, a solution will be provided.\n\nThe problem describes a process of sampling $n$ mitochondrial deoxyribonucleic acid (mtDNA) genomes from a maternal pool where the proportion of mutant mtDNA is $h$. Each of the $n$ draws is an independent event. Let us define the outcome of a single draw as a random variable. A draw can either be a mutant genome or a wild-type genome. This constitutes a Bernoulli trial.\n\nLet a \"success\" be the event of drawing a mutant mtDNA molecule. The probability of success in any single trial is given as $p=h$. Consequently, the probability of \"failure\" (drawing a wild-type genome) is $1-p = 1-h$.\n\nThe problem states that $n$ such independent draws are made. The total number of mutant mtDNA molecules in the offspring sample, denoted by $k$, is the total number of successes in these $n$ independent Bernoulli trials. A random variable defined in this manner follows a binomial distribution. We can write this as $k \\sim B(n, h)$, where $n$ is the number of trials and $h$ is the probability of success.\n\nThe probability mass function (PMF) for a binomial distribution, which gives the probability of observing exactly $j$ successes in $n$ trials, is:\n$$ \\mathbb{P}(k=j) = \\binom{n}{j} h^{j} (1-h)^{n-j} $$\nwhere $\\binom{n}{j} = \\frac{n!}{j!(n-j)!}$ is the binomial coefficient, and $j$ is an integer such that $0 \\le j \\le n$.\n\nThe problem states that a clinical manifestation of the disease is predicted if the offspring's heteroplasmy level, $k/n$, meets or exceeds a pathogenic threshold, $h_c$. We are asked to derive an expression for the probability of this event, $\\mathbb{P}(k/n \\ge h_c)$.\n\nWe can rearrange the inequality to express the condition in terms of the integer random variable $k$:\n$$ \\frac{k}{n} \\ge h_c \\iff k \\ge n h_c $$\nSince $k$ must be an integer, the smallest integer value of $k$ that satisfies this condition is $\\lceil n h_c \\rceil$, where $\\lceil \\cdot \\rceil$ denotes the ceiling function, which maps a real number to the least integer greater than or equal to it. Let us define this minimum number of mutant molecules as $k_{min} = \\lceil n h_c \\rceil$.\n\nThe event $k \\ge k_{min}$ is the union of the mutually exclusive events $\\{k=k_{min}, k=k_{min}+1, \\ldots, k=n\\}$. The probability of this event is the sum of the probabilities of these individual outcomes:\n$$ \\mathbb{P}\\left(\\frac{k}{n} \\ge h_c\\right) = \\mathbb{P}(k \\ge k_{min}) = \\sum_{j=k_{min}}^{n} \\mathbb{P}(k=j) $$\nSubstituting the binomial PMF, we get:\n$$ \\mathbb{P}\\left(\\frac{k}{n} \\ge h_c\\right) = \\sum_{j=\\lceil n h_c \\rceil}^{n} \\binom{n}{j} h^{j} (1-h)^{n-j} $$\nThis expression represents the cumulative probability of the upper tail of a binomial distribution. The problem asks for a closed-form analytic expression, which can be achieved using a standard special function. The sum is directly related to the regularized incomplete beta function.\n\nThe regularized incomplete beta function, denoted $I_x(a, b)$, is defined as the ratio of the incomplete beta function $B_x(a, b)$ to the complete beta function $B(a, b)$:\n$$ I_x(a, b) = \\frac{B_x(a, b)}{B(a, b)} $$\nwhere the incomplete beta function is given by the integral:\n$$ B_x(a, b) = \\int_{0}^{x} t^{a-1} (1-t)^{b-1} dt \\quad \\text{for } 0 \\le x \\le 1 $$\nand the complete beta function is:\n$$ B(a, b) = \\int_{0}^{1} t^{a-1} (1-t)^{b-1} dt $$\nThere exists a fundamental identity that relates the tail probability of the binomial distribution to the regularized incomplete beta function:\n$$ \\sum_{j=k_0}^{n} \\binom{n}{j} p^{j} (1-p)^{n-j} = I_p(k_0, n - k_0 + 1) $$\nTo apply this identity to our problem, we set the probability of success $p = h$ and the lower limit of summation $k_0 = \\lceil n h_c \\rceil$. The parameters for the regularized incomplete beta function are then $x=h$, $a = \\lceil n h_c \\rceil$, and $b = n - \\lceil n h_c \\rceil + 1$.\n\nTherefore, the closed-form analytic expression for the probability that the offspring heteroplasmy meets or exceeds the pathogenic threshold is:\n$$ \\mathbb{P}\\left(\\frac{k}{n} \\ge h_c\\right) = I_h(\\lceil n h_c \\rceil, n - \\lceil n h_c \\rceil + 1) $$", "answer": "$$\n\\boxed{I_{h}(\\lceil n h_c \\rceil, n - \\lceil n h_c \\rceil + 1)}\n$$", "id": "4801213"}]}